Atossa_Therapeutics_logo-min.png
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
28 juin 2023 09h15 HE | Atossa Therapeutics, Inc.
SEATTLE and SAN FRANCISCO, June 28, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
27 janv. 2022 09h30 HE | Atossa Therapeutics, Inc.
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
21 oct. 2021 09h30 HE | Atossa Therapeutics, Inc.
SEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative...